ESSA Pharma (NASDAQ:EPIX) fell above 18% premarket on Wednesday after the company revised terms of its merger with biotech firm XenoTherapeutics, lowering expected shareholder payout due to potential liabilities and updated cash estimates. Under the amended agreement, ESSA shareholders are now ...